Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Short-term Investments (2023 - 2025)

Collegium Pharmaceutical (COLL) has 3 years of Short-term Investments data on record, last reported at $135.8 million in Q3 2025.

  • For Q3 2025, Short-term Investments rose 67.62% year-over-year to $135.8 million; the TTM value through Sep 2025 reached $135.8 million, up 67.62%, while the annual FY2024 figure was $25.0 million, 65.08% down from the prior year.
  • Short-term Investments reached $135.8 million in Q3 2025 per COLL's latest filing, up from $19.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $135.8 million in Q3 2025 and bottomed at $19.8 million in Q2 2025.
  • Average Short-term Investments over 3 years is $62.9 million, with a median of $58.8 million recorded in 2023.
  • Peak YoY movement for Short-term Investments: skyrocketed 136.66% in 2024, then crashed 79.9% in 2025.
  • A 3-year view of Short-term Investments shows it stood at $71.6 million in 2023, then crashed by 65.08% to $25.0 million in 2024, then soared by 443.07% to $135.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $135.8 million in Q3 2025, $19.8 million in Q2 2025, and $19.9 million in Q1 2025.